North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care
- 25 April 1998
- Vol. 316 (7140) , 1303-1309
- https://doi.org/10.1136/bmj.316.7140.1303
Abstract
Patients who have had cardiovascular disease and stroke are treated with aspirin to reduce their subsequent risk of vascular events or death and thereby to increase the length and quality of their life. This guideline aims to provide general practitioners with evidence linked recommendations on the use of aspirin as secondary prophylaxis for cardiovascular disease and stroke in patients at high risk of these disorders. It is assumed that doctors will use their knowledge and clinical judgment in managing individual patients in the light of available resources. Recommendations may not be appropriate for use in all circumstances. This is a summary of the full version of the guideline.1 #### Summary points The use of aspirin in the secondary prophylaxis of vascular disease is cost effective Aspirin should be used in patients with acute myocardial infarction, prior myocardial infarction, stable and unstable angina, and prior stroke or transient ischaemic attack In acute myocardial infarction a dose of 150 mg daily should be used In the other indications a dose of 75 mg daily should be used In general practice, patients with a raised risk of vascular disease present with several disorders—acute or previous myocardial infarction, unstable or stable angina, transient ischaemic attacks, and peripheral vascular disease. The incidence and prevalence of these conditions and the workload associated with them in general practice can be estimated from the recent national morbidity survey in general practice for England and Wales, and is shown in the table.2 View this table: Diseases associated with a raised risk of vascular events—incidence, prevalence, and workload in a general practice, assuming a list size of 2000 patients Throughout this guideline the strength of statements on evidence and of recommendations is categorised according to the scheme discussed in the first paper in the series.3 The box below shows these categories in descending …Keywords
This publication has 100 references indexed in Scilit:
- Danish very-low-dose aspirin after carotid endarterectomy trial.Stroke, 1988
- The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results.Stroke, 1988
- Aspirin, Sulfinpyrazone, or Both in Unstable AnginaNew England Journal of Medicine, 1985
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaNew England Journal of Medicine, 1983
- The Anturane Reinfarction Trial: Reevaluation of OutcomeNew England Journal of Medicine, 1982
- The FDA's Critique of the Anturane Reinfarction TrialNew England Journal of Medicine, 1980
- Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.Circulation, 1980
- The Canadian trial of aspirin and sulfinpyrazone in threatened strokeAmerican Heart Journal, 1980
- Sulfinpyrazone in the Prevention of Sudden Death after Myocardial InfarctionNew England Journal of Medicine, 1980
- A Randomized Trial of Aspirin and Sulfinpyrazone in Threatened StrokeNew England Journal of Medicine, 1978